{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T09:00:50Z","timestamp":1770973250545,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ymgme.2024.108347","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T17:15:29Z","timestamp":1707844529000},"page":"108347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Breaking the chains of lipoprotein lipase deficiency: A pediatric perspective on the efficacy and safety of Volanesorsen"],"prefix":"10.1016","volume":"142","author":[{"given":"Bibiche","family":"den Hollander","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion M.","family":"Brands","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilse J.M.","family":"Nijhuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lous J.A.E.","family":"Doude van Troostwijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"van Essen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geesje H.","family":"Hofsteenge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart G.","family":"Koot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annelieke R.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura A.","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik S.G.","family":"Stroes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M.","family":"van de Ven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Wiegman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara D.M.","family":"van Karnebeek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ymgme.2024.108347_bb0005","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1194\/jlr.R009720","article-title":"Genetic determinants of plasma triglycerides","volume":"52","author":"Johansen","year":"2011","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108347_bb0010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jacl.2017.12.015","article-title":"Roundtable on etiology of familial chylomicronemia syndrome","volume":"12","author":"Brown","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.ymgme.2024.108347_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2016.10.002","article-title":"Diagnostic algorithm for familial chylomicronemia syndrome","volume":"23","author":"Stroes","year":"2017","journal-title":"Atheroscler. Suppl."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108347_bb0020","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2796.2012.02516.x","article-title":"Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia","volume":"272","author":"Surendran","year":"2012","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ymgme.2024.108347_bb0025","series-title":"Familial lipoprotein lipase deficiency","author":"Brunzell","year":"1999"},{"key":"10.1016\/j.ymgme.2024.108347_bb0030","first-page":"249","article-title":"Chylomicronemia syndrome","volume":"37","author":"Chait","year":"1992","journal-title":"Adv. Intern. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108347_bb0035","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jacl.2010.11.004","article-title":"Etiology and risk of lactescent plasma and severe hypertriglyceridemia","volume":"5","author":"Tremblay","year":"2011","journal-title":"J. Clin. Lipidol."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108347_bb0040","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ymgme.2007.10.007","article-title":"Monogenic pediatric dyslipidemias: classification, genetics and clinical spectrum","volume":"93","author":"Rahalkar","year":"2008","journal-title":"Mol. Genet. Metab."},{"issue":"19","key":"10.1016\/j.ymgme.2024.108347_bb0045","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1177\/2047487319888054","article-title":"Prevalence of familial chylomicronemia syndrome in a quaternary care center","volume":"27","author":"Pallazola","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"147","key":"10.1016\/j.ymgme.2024.108347_bb0050","first-page":"101","article-title":"Hypertriglyceridemia-induced acute pancreatitis: progress on disease mechanisms and treatment modalities","volume":"27","author":"Guo","year":"2019","journal-title":"Discov. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108347_bb0055","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0025-7125(16)31430-4","article-title":"Chylomicronemia syndrome. Interaction of genetic and acquired hypertriglyceridemia","volume":"66","author":"Brunzell","year":"1982","journal-title":"Med. Clin. North Am."},{"issue":"5","key":"10.1016\/j.ymgme.2024.108347_bb0060","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1742-1241.2007.01678.x","article-title":"An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?","volume":"62","author":"Chan","year":"2008","journal-title":"Int. J. Clin. Pract."},{"issue":"10","key":"10.1016\/j.ymgme.2024.108347_bb0065","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1042\/CS20070308","article-title":"Apolipoprotein C-III: understanding an emerging cardiovascular risk factor","volume":"114","author":"Ooi","year":"2008","journal-title":"Clin. Sci. (Lond.)"},{"issue":"47","key":"10.1016\/j.ymgme.2024.108347_bb0070","doi-asserted-by":"crossref","first-page":"33997","DOI":"10.1074\/jbc.M113.495366","article-title":"Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets","volume":"288","author":"Larsson","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.ymgme.2024.108347_bb0075","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1080\/07853890310011969","article-title":"Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients","volume":"35","author":"Lemieux","year":"2003","journal-title":"Ann. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108347_bb0080","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/MED.0000000000000136","article-title":"Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease","volume":"22","author":"Kohan","year":"2015","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108347_bb0085","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/0014-5793(76)80145-7","article-title":"Effect of serum and C-apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase","volume":"65","author":"Kinnunen","year":"1976","journal-title":"FEBS Lett."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108347_bb0090","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1161\/ATVBAHA.109.197830","article-title":"Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins","volume":"30","author":"Mendivil","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108347_bb0095","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/CIRCRESAHA.110.219188","article-title":"Impact of combined deficiency of hepatic lipase and endothelial lipase on the metabolism of both high-density lipoproteins and apolipoprotein B-containing lipoproteins","volume":"107","author":"Brown","year":"2010","journal-title":"Circ. Res."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108347_bb0100","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/MOL.0b013e328352dc70","article-title":"Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production","volume":"23","author":"Yao","year":"2012","journal-title":"Curr. Opin. Lipidol."},{"issue":"5","key":"10.1016\/j.ymgme.2024.108347_bb0105","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1172\/JCI116066","article-title":"Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles","volume":"90","author":"Aalto-Set\u00e4l\u00e4","year":"1992","journal-title":"J. Clin. Invest."},{"issue":"50","key":"10.1016\/j.ymgme.2024.108347_bb0110","doi-asserted-by":"crossref","first-page":"31348","DOI":"10.1074\/jbc.272.50.31348","article-title":"Inhibitory effects of specific apolipoprotein C-III isoforms on the binding of triglyceride-rich lipoproteins to the lipolysis-stimulated receptor","volume":"272","author":"Mann","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"4970","key":"10.1016\/j.ymgme.2024.108347_bb0115","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1126\/science.2167514","article-title":"Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice","volume":"249","author":"Ito","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.ymgme.2024.108347_bb0120","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.2147\/DDDT.S224771","article-title":"Volanesorsen in the treatment of familial chylomicronemia syndrome or hypertriglyceridaemia: design, development and place in therapy","volume":"14","author":"Esan","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ymgme.2024.108347_bb0125","author":"Committee"},{"issue":"6","key":"10.1016\/j.ymgme.2024.108347_bb0130","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108347_bb0135","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/MPG.0000000000000780","article-title":"Acute pancreatitis in the pediatric intensive care unit","volume":"61","author":"Goday","year":"2015","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108347_bb0140","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jacl.2018.04.009","article-title":"The burden of familial chylomicronemia syndrome: results from the global IN-FOCUS study","volume":"12","author":"Davidson","year":"2018","journal-title":"J. Clin. Lipidol."},{"issue":"5","key":"10.1016\/j.ymgme.2024.108347_bb0145","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/jimd.12605","article-title":"Development of medicines for rare diseases and inborn errors of metabolism: toward novel public-private partnerships","volume":"46","author":"Rosenberg","year":"2023","journal-title":"J. Inherit. Metab. Dis."},{"issue":"5","key":"10.1016\/j.ymgme.2024.108347_bb0150","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1399-0004.2009.01369.x","article-title":"Pink-creamy whole blood in a 3-month-old infant with a homozygous deletion in the lipoprotein lipase gene","volume":"77","author":"Avis","year":"2010","journal-title":"Clin. Genet."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108347_bb0155","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0015-0282(16)48681-4","article-title":"Variations in serum lipids and lipoproteins throughout the menstrual cycle","volume":"44","author":"Ahumada Hemer","year":"1985","journal-title":"Fertil. Steril."},{"issue":"6","key":"10.1016\/j.ymgme.2024.108347_bb0160","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1367\/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2","article-title":"The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity","volume":"3","author":"Varni","year":"2003","journal-title":"Ambul. Pediatr."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108347_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11040982","article-title":"Volanesorsen: a new era in the treatment of severe hypertriglyceridemia","volume":"11","author":"Kolovou","year":"2022","journal-title":"J. Clin. Med."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108347_bb0175","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.0954-6820.1987.tb00900.x","article-title":"Hypertriglyceridemia--acute pancreatitis--ischemic heart disease. A case study in a pair of monozygotic twins","volume":"221","author":"Lithell","year":"1987","journal-title":"Acta Med. Scand."},{"issue":"8","key":"10.1016\/j.ymgme.2024.108347_bb0180","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1503\/cmaj.060963","article-title":"Hypertriglyceridemia: its etiology, effects and treatment","volume":"176","author":"Yuan","year":"2007","journal-title":"Cmaj"},{"issue":"3","key":"10.1016\/j.ymgme.2024.108347_bb0185","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0022-3476(98)70280-X","article-title":"Familial lipoprotein lipase deficiency in infancy: clinical, biochemical, and molecular study","volume":"133","author":"Feoli-Fonseca","year":"1998","journal-title":"J. Pediatr."},{"issue":"8","key":"10.1016\/j.ymgme.2024.108347_bb0190","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ejim.2014.08.008","article-title":"Current knowledge of hypertriglyceridemic pancreatitis","volume":"25","author":"Valdivielso","year":"2014","journal-title":"Eur. J. Intern. Med."},{"issue":"5","key":"10.1016\/j.ymgme.2024.108347_bb0195","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMc2306575","article-title":"Volanesorsen to prevent acute pancreatitis in hypertriglyceridemia","volume":"390","author":"Alexander","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"6 Pt 2","key":"10.1016\/j.ymgme.2024.108347_bb0200","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0002-9378(16)32478-4","article-title":"Effects of oral contraceptives on lipoprotein triglyceride and cholesterol: relationships to estrogen and progestin potency","volume":"142","author":"Knopp","year":"1982","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108347_bb0205","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1210\/jcem-57-2-262","article-title":"The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females","volume":"57","author":"Schaefer","year":"1983","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ymgme.2024.108347_bb0210","series-title":"European Medicines Agency. Volanesorsen (Waylivra): Public Assessment Report Amsterdam","author":"Agency","year":"2019"},{"issue":"23","key":"10.1016\/j.ymgme.2024.108347_bb0215","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"3 Suppl","key":"10.1016\/j.ymgme.2024.108347_bb0220","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.1097\/00005650-198903001-00018","article-title":"Generic and disease-specific measures in assessing health status and quality of life","volume":"27","author":"Patrick","year":"1989","journal-title":"Med. Care"},{"issue":"5","key":"10.1016\/j.ymgme.2024.108347_bb0225","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jacl.2022.06.005","article-title":"Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia","volume":"16","author":"Karwatowska-Prokopczuk","year":"2022","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.ymgme.2024.108347_bb0230","doi-asserted-by":"crossref","first-page":"4721357","DOI":"10.1155\/2018\/4721357","article-title":"Management of hypertriglyceridemia induced acute pancreatitis","volume":"2018","author":"Garg","year":"2018","journal-title":"Biomed. Res. Int."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719224002324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719224002324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T17:15:38Z","timestamp":1735233338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719224002324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1096719224002324"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2024.108347","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breaking the chains of lipoprotein lipase deficiency: A pediatric perspective on the efficacy and safety of Volanesorsen","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2024.108347","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108347"}}